Literature DB >> 8841095

Disposition and analgesic effects of systemic morphine, morphine-6-glucuronide and normorphine in rat.

J Hasselström1, J O Svensson, J Säwe, Z Wiesenfeld-Hallin, Q Y Yue, X J Xu.   

Abstract

Morphine, morphine-6-glucuronide and normorphine were administered to male Sprague-Dawley-rats. Analgesic effect was estimated with the hot plate and spinal nociceptive reflex depression. After intraperitoneal administration the molar potency ratio of morphine-6-glucuronide/morphine was 1.7 estimated by the paw lick latency on the hot plate utilizing a linked pharmacokinetic-pharmacodynamic model. The potency ratio of morphine-6-glucuronide/morphine utilizing the spinal nociceptive reflex depression after intravenous administration was estimated to be within the earlier reported range of 1-4 after systemic administration of the drugs. In contrast to what is seen in man virtually no morphine-6-glucuronide was formed in Sprague-Dawley rats after administration of morphine, much lower levels of morphine-3-glucuronide were also seen. The molar AUC ratio of morphine-3-glucuronide/morphine was 1.8 +/- 0.5 and the corresponding ratio for normorphine/morphine was 0.2 +/- 0.06. After intraperitoneal administration of morphine, morphine-6-glucuronide and normorphine mean systemic clearance values of 413 +/- 95, 50 +/- 11 and 187 +/- 54 ml.min.kg-1 respectively were observed. Varea was 9.0 +/- 2.1, 0.8 +/- 0.2 and 4.9 +/- 1.4 L.kg-1 respectively. The slow absorption of morphine-6-glucuronide was illustrated by the mean Tmax-value of the 16 min. as compared with 9 min. for morphine and 10 min. for normorphine. It was possible to fit pharmacokinetic and pharmacodynamic data of behavioural analgesic effect of both morphine and morphine-6-glucuronide to a parametric model linking the sigmoid Emax model to standard pharmacokinetic equations.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8841095     DOI: 10.1111/j.1600-0773.1996.tb00239.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  5 in total

1.  Blood-brain barrier transport and brain distribution of morphine-6-glucuronide in relation to the antinociceptive effect in rats--pharmacokinetic/pharmacodynamic modelling.

Authors:  M R Bouw; R Xie; K Tunblad; M Hammarlund-Udenaes
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

Review 2.  Pharmacokinetics of opioids in liver disease.

Authors:  I Tegeder; J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

3.  Elevated concentrations of morphine 6-beta-D-glucuronide in brain extracellular fluid despite low blood-brain barrier permeability.

Authors:  F Stain-Texier; G Boschi; P Sandouk; J M Scherrmann
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

4.  Endogenous opioids inhibit early-stage pancreatic pain in a mouse model of pancreatic cancer.

Authors:  Molly A Sevcik; Beth M Jonas; Theodore H Lindsay; Kyle G Halvorson; Joseph R Ghilardi; Michael A Kuskowski; Pinku Mukherjee; John E Maggio; Patrick W Mantyh
Journal:  Gastroenterology       Date:  2006-09       Impact factor: 22.682

5.  Intravenous ibandronate rapidly reduces pain, neurochemical indices of central sensitization, tumor burden, and skeletal destruction in a mouse model of bone cancer.

Authors:  Kyle G Halvorson; Molly A Sevcik; Joseph R Ghilardi; Lucy J Sullivan; Nathan J Koewler; Frieder Bauss; Patrick W Mantyh
Journal:  J Pain Symptom Manage       Date:  2008-04-14       Impact factor: 3.612

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.